HLB BioStep partners with Nexel to integrate organoid‑based alternative testing with nonclinical studies
HLB BioStep and organoid specialist Nexel signed an MOU to combine hiPSC‑derived organoid toxicity/efficacy data with HLB’s nonclinical testing, creating an integrated evaluation service for pharma and biotech firms.